The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland.

The drug is currently being jointly developed by Genmab and Johnson & Johnson subsidiary Janssen Biotech, which has procured worldwide commercialisation rights to the treatment from Genmab.

Daratumumab is the first new immunotherapy drug that has been approved for the treatment of patients with myeloma in the UK.

It belongs to a group of medicines known as monoclonal antibodies and works by using the patient’s own immune system to combat myeloma cells in order to either kill them or stop them from growing.

Approved as a monotherapy, the drug can be used as a fourth line treatment option for patients with relapsed and/or refractory myeloma, whose prior treatment has included a proteasome inhibitor drug, such as bortezomib (Velcade), and an immunomodulatory drug, such as lenalidomide (Revlimid).

The treatment can also be used on patients who have demonstrated disease progression on their last treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Daratumumab is an exciting and innovative new treatment which has been shown to have a very beneficial effect on length of remission in patients who respond.”

Myeloma UK chief executive Rosemarie Finley said: “This is great news for myeloma patients in Scotland and their families.

“Daratumumab is an exciting and innovative new treatment which has been shown to have a very beneficial effect on length of remission in patients who respond.

“Despite the welcome approval of new drugs in recent years, there is still an urgent need for new myeloma treatments; especially for relapsed patients who have exhausted other standard treatment options. Today’s approval gives myeloma patients whose cancer has come back an important new treatment option.”

Myeloma UK is the only organisation in the country that focuses on dealing with myeloma.


Image: Daratumumab injection. Photo: courtesy of Myeloma UK.